Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

Defective VHL protein is also present in most cases of advanced clear cell renal cell carcinoma (RCC), so a recommendation ...

EU regulators recommend approval of Merck's drug Welireg for certain patients with VHL disease or advanced kidney cancer.

A biopsy reveals squamous cell carcinoma (SCC) in situ ... Two stages of Mohs surgery were required to clear the tumor, which involved not only the entire extent of the proximal nail fold ...

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Phase 2 data suggest that metastectomy in renal cell carcinoma may be associated with delayed disease progression and ...

Merck (NYSE: MRK) shares decreased in price Friday, on word the European Medicines Agency's Committee for Medicinal Products ...

Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

Nisevokitug is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Myelofibrosis;Post-Polycythemia Vera Myelofibrosis (PPV-MF);Post-Essential Thrombocythemia ...

Weill Cornell Medicine has received a four-year, $1.4 million grant from the U.S. Department of Defense to investigate a new therapeutic approach for ...